molecules of the month

LEO Pharma IL-17A modulator

oral, allosteric IL-17A inactivator prodrug

Ph. I for psoriasis

SBDD from known compound


LEO Pharma, Ballerup, DK

2 mins read

IL-17 has been a hot target in immunology thanks to the clinical and commercial success of marketed anti-IL-17A and anti-IL-17RA antibody drugs secukinumab (Cosentyx), ixekizumab (Talz), and brodalumab (Siliq) in psoriasis, psoriatic arthritis, and ankylosing sponylitis. With the recent identification of small molecule binders of IL-17A, excitement has grown around the possibility that small molecule alternatives to antibody drugs may be feasible. Cytokines and cytokine receptors like interleukins have traditionally been the domain of biologic drugs due to the need to prevent protein-protein interactions (PPIs) between the cytokines and their receptors. While several companies have patented small molecule IL-17A antagonists, including Ensemble, DiCE, and Lilly, LEO Pharma’s molecule is the most advanced and disclosed oral candidate. The active ingredient was…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: